Celebrating 40 Years: An In-Depth Examination of the FDA Orange Book
October 27 - 28, 2020
Webcast
Learners will go in-depth into FDA's Orange Book and generics. Healthcare professionals will discover how Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) identifies drug products approved on the basis of safety and effectiveness.
- Draft guidance for industry, Orange Book Questions and Answers https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orange-book-questions-and-answers-guidance-industry
- Orange Book https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
- Identify and use the various types of information in the Orange Book, including therapeutic equivalence ratings, patents, exclusivities, and more.
- Describe the origin and history of the Orange Book.
This activity is intended for physicians, pharmacists, and nurses.
Day 1 October 27, 2020
Time | Topic | Speaker |
---|---|---|
8:30 - 8:45 AM EDT | Overview | Brenda Stodart, PharmD, MS, BCGP, RAC |
8:45 - 9:00 AM EDT | Keynote Opening Remarks | Sally Choe, PhD |
9:00 - 9:45 AM EDT | FDA's Orange Book: A Historical Review of 40 Years | Kendra Stewart |
9:45 - 10:30 AM EDT | Orange Book 101: An Overview of FDA's Orange Book | Camille Smith, PharmD |
10:30 - 10:50 AM EDT | Break | |
10:50 - 11:50 AM EDT | How to Update Orange Book Information and Related Considerations: Marketing Status Changes: 506I reporting, Drug Shortages, and Transfer of Ownership Updates |
Kendra Stewart Kun Shen, PharmD Eunice Chung-Davies, PharmD |
11:50 - 12:05 PM EDT | Questions and Panel Discussion |
Kendra Stewart Kun Shen, PharmD Eunice Chung-Davies, PharmD Elizabeth Friedman, JD |
12:05 - 1:05 PM EDT | Lunch | |
1:05 - 1:35 PM EDT | An Overview of FDA's Patent Listing Process | Kun Shen, PharmD |
1:35 - 2:35 PM EDT | Changes to Orange Book Patent Information | Alicia Chen, PharmD |
2:35 - 2:50 PM EDT | Panel Discussion |
Kun Shen, PharmD Alicia Chen, PharmD Janice Weiner, JD, MPH |
2:50 - 3:10 PM EDT | Break | |
3:10 - 3:40 PM EDT | The Patent Information Dispute Process | Alicia Chen, PharmD |
3:40 - 4:20 PM EDT | Best Practices for 505(b)(2) and ANDA Applicants |
Mary Ann Holovac, R. Ph Andrew Coogan, PharmD |
4:20 - 4:40 PM EDT | Panel Discussion and Closing Remarks |
Alicia Chen, PharmD Mary Ann Holovac, R. Ph Jennifer Gerton, JD Andrew Coogan, PharmD |
Time | Topic | Speaker |
---|---|---|
8:45 - 9:00 AM EDT | Day Two Overview |
Brenda Stodart, PharmD, MS, BCGP, RAC Kendra Stewart |
9:00 - 9:15 AM EDT | Orange Book Exclusivity: An Introduction and Overview | Truong Quach, PharmD |
9:15 - 9:45 AM EDT | Orange Book Exclusivity: Part I - NCE and 3-Year | Nisha Shah, JD, M.Sc. |
9:45 - 10:00 AM EDT | Panel Discussion |
Alicia Chen, PharmD Truong Quach, PharmD Nisha Shah, JD, M.Sc. Christopher Pruitt, JD |
10:00 - 10:20 AM EDT | Break | |
10:20 - 11:05 AM EDT | Orange Book Exclusivity: Part II - Pediatric, Orphan, and GAIN |
Kristiana Brugger, JD, LL.M. Aaron Friedman, JD Katherine Schumann, MS |
11:05 - 11:50 AM EDT | Orange Book Exclusivity: Part III - 180-Day and Competitive Generic Therapy Exclusivities |
Jonathan Hughes, JD Mindy Ehrenfried, JD |
11:50 - 12:05 PM EDT | Panel Discussion |
Kristiana Brugger, JD, LL.M. Aaron Friedman, JD Katherine Schumann, MS Jonathan Hughes, JD Mindy Ehrenfried, JD |
12:05 - 1:05 PM EDT | Lunch | |
1:05 - 1:35 PM EDT | Orange Book: An Overview of Therapeutic Equivalence | Elizabeth Friedman, JD |
1:35 - 1:50 PM EDT | Panel Discussion |
Kendra Stewart Elizabeth Friedman, JD James Myers, JD |
1:50 - 2:35 PM EDT | Referencing Approved Drug Products in ANDA Submissions |
JAMES HANRATTY, JD Timothy Kim, PharmD |
2:35 - 2:50 PM EDT | Panel Discussion |
Kendra Stewart JAMES HANRATTY, JD Timothy Kim, PharmD Susan Levine, JD |
2:50 - 3:10 PM EDT | Break | |
3:10 - 3:40 PM EDT | Orange Book: Looking Towards the Future | Kendra Stewart |
3:40 - 3:50 PM EDT | Closing Review |
Kendra Stewart Maryll Toufanian, JD |
![Jointly Accredited Provider](https://ceportal.fda.gov//files/content/docs/logo-joint-accreditation-provider.png)
![ICPE Credit](https://ceportal.fda.gov//files/content/docs/icpeCreditLogo.png)
Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Faculty
- Brugger, Kristiana, JD, LL.M., Regulatory Counsel, Office of Regulatory Policy, CDER, FDA - nothing to disclose
- Chen, Alicia, PharmD, Deputy Director, FDA - nothing to disclose
- Choe, Sally, PhD, Director, FDA/CDER/OGD - nothing to disclose
- Chung-Davies, Eunice, PharmD, Pharmacist, FDA - nothing to disclose
- Coogan, Andrew, PharmD, Pharmacist, FDA - nothing to disclose
- Ehrenfried, Mindy, JD, Regulatory Counsel, FDA-CDER-OGD - nothing to disclose
- Friedman, Aaron, JD, Senior Regulatory Counsel, FDA/OCPP/OOPD - nothing to disclose
- Friedman, Elizabeth, JD, Regulatory Counsel, Office of Pharmaceutical Quality - nothing to disclose
- Gerton, Jennifer, JD, Associate Chief Counsel, Office of the Chief Counsel - nothing to disclose
- HANRATTY, JAMES, JD, Regulatory Counsel, CDER, Office of Generic Drugs, Division of Policy Development - nothing to disclose
- Holovac, Mary Ann, R. Ph, Clinical Analyst, FDA/CDER - nothing to disclose
- Hughes, Jonathan, JD, Regulatory Counsel, FDA/CDER/OGD/OGDP - nothing to disclose
- Kim, Timothy, PharmD, Division Director, FDA I received Other - PRN hourly wage from George Washington University Hospital for a role as Employee.
- Levine, Susan, JD, Deputy Director, Division of Policy Development, Office of Generic Drug Policy - nothing to disclose
- Myers, James, JD, Associate Director for Policy, FDA, CBER - nothing to disclose
- Pruitt, Christopher, JD, Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy My spouse received Salary from Adventist Health Care, Gaithersburg, MD for a role as Employee.
- Quach, Truong, PharmD, Pharmacist, FDA - nothing to disclose
- Schumann, Katherine, MS, Deputy Director, Division of Regulatory Policy, Office of New Drug Policy - nothing to disclose
- Shah, Nisha, JD, M.Sc., Senior Regulatory Counsel, U.S. Food and Drug Administration, Center for Drug Evaluation and Research - nothing to disclose
- Shen, Kun, PharmD, Pharmacist, FDA/CDER/OGD/OGDP/DLRS - nothing to disclose
- Smith, Camille, PharmD, Pharmacist, FDA - nothing to disclose
- Stewart, Kendra, Supervisor, Orange Book, CDER - nothing to disclose
- Stodart, Brenda, PharmD, MS, BCGP, RAC, Program Director, FDA - nothing to disclose
- Toufanian, Maryll, JD, Director, Office of Generic Drug Policy, CDER Office of Generic Drugs - nothing to disclose
- Weiner, Janice, JD, MPH, Principal Regulatory Counsel, FDA/CDER/Office of Regulatory Policy - nothing to disclose
Planning Committee
- Kleppinger, Cynthia, MD, Medical Officer, FDA - nothing to disclose
- Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI - nothing to disclose
- Stodart, Brenda, PharmD, MS, BCGP, RAC, Program Director, FDA - nothing to disclose
CE Consultation and Accreditation Team
- Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration is complimentary; therefore refunds are not applicable.
Must attend 85% of the activity.